SCHEMBL942166

SCHEMBL942166

CN(C)c1ccc(NC(=O)c2cc3cc([Si](C)(C)C)ccc3n2Cc2cccc(F)c2)cn1

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
F10 P00742 4/20 0.44
ECE1 P42892 9/20 0.42
MAOB P27338 1/20 0.41
CXCR1 P25024 1/20 0.40
CXCR2 P25025 1/20 0.40
ABCB1 P08183 1/20 0.39
PIK3CA P42336 1/20 0.39
MTOR P42345 1/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.39
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4150411 0.93 F10 (0.47) F10ECE1MAOBCXCR1CXCR2
Hydrochloric Acid SCHEMBL4143378 0.92 F10 (0.47) F10ECE1MAOBCXCR1CXCR2
SCHEMBL4150551 0.89 PPARG (0.46) F10ECE1GRIN1GRIN2B
SCHEMBL4158624 0.88 PTGDR2 (0.45) F10ECE1MAOBCXCR1CXCR2
SCHEMBL4151209 0.87 ECE1 (0.50) F10ECE1PTGDR2
SCHEMBL4151515 0.85 MAPT (0.48) F10ECE1MAOBPIK3CAMTOR
SCHEMBL942092 0.85 KCNQ3 (0.42) F10ECE1MAOBABCB1
SCHEMBL939898 0.83 ECE1 (0.40) F10ECE1MAOBABCB1GRIN1
SCHEMBL1101510 0.81 CXCR1 (0.40) F10MAOBCXCR1CXCR2PIK3CA
SCHEMBL4143406 0.80 F10 (0.45) F10ECE1PTGDR2GRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399491-B2 Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-19 US claimed
EP-2235003-B1 DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-12-19 EP claimed
US-20110009365-A1 DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 US claimed
CN-102143956-B Derivatives of indole-2-carboxamides and azaindole-2-carboxamides substituted by silane groups, preparation thereof and therapeutic use thereof SANOFI AVENTIS 2014-04-23 CN disclosed
US-8399491-B2 Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-19 US disclosed
EP-2235003-B1 DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-12-19 EP disclosed
US-20110009365-A1 DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009365-A1 DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF IDO2, INMT, IDO1 F10 2604/4885ECE1 3191/4885MAOB 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.